Lv41
630 积分 2023-01-17 加入
Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton’s Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies
4天前
已完结
Finding a needle in the haystack: ADME and pharmacokinetics/pharmacodynamics characterization and optimization toward orally available bifunctional protein degraders
4天前
已完结
Discovery of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates Targeting MYD88 Mutant Diffuse Large B-Cell Lymphoma
21天前
已完结
Ligands for cereblon: 2017–2021 patent overview
1个月前
已完结
A selective small-molecule STAT5 PROTAC degrader capable of achieving tumor regression in vivo
1个月前
已完结
Discovery of a Potent and Selective STAT5 PROTAC Degrader with Strong Antitumor Activity In Vivo in Acute Myeloid Leukemia
1个月前
已完结
Developments of CRBN-based PROTACs as potential therapeutic agents
1个月前
已完结
A covalent fragment-based strategy targeting a novel cysteine to inhibit activity of mutant EGFR kinase
4个月前
已完结
LYTACs: An Emerging Tool for the Degradation of Non‐Cytosolic Proteins
5个月前
已完结
NOVEL APPROACHES IN TARGETING MEMBRANE AND SECRETED PROTEINS FOR LYSOSOMAL DEGRADATION
5个月前
已完结
皖公网安备34019202002308
